Apogee Therapeutics Funding: $169M Raised, Series B (2022)
Apogee Therapeutics is based in Waltham, MA. It has raised $169M in total funding. Latest round: Series B.
Apogee Therapeutics funding overview
Apogee Therapeutics is based in Waltham, MA. Apogee Therapeutics has raised $169M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in December 2022. The round record for Apogee Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include Deep Track Capital, RTW Investments, LP, Fidelity Management & Research Company, OrbiMed, Perceptive Xontogeny Ventures Fund II, RA Capital Management and 3 others. 9 distinct backers are named across the disclosed rounds.
Apogee Therapeutics at a glance
Total raised
$169M
Latest round
Series B
Latest round date
December 2022
Headquarters
Waltham, MA
Notable investors
Deep Track Capital, RTW Investments, LP, Fidelity Management & Research Company, OrbiMed, Perceptive Xontogeny Ventures Fund II, RA Capital Management, Wellington Management, Fairmount
Frequently asked about Apogee Therapeutics funding
How much has Apogee Therapeutics raised?
Apogee Therapeutics has raised $169M in total disclosed funding across the rounds on record.
Who has invested in Apogee Therapeutics?
Deep Track Capital, RTW Investments, LP, Fidelity Management & Research Company, OrbiMed, Perceptive Xontogeny Ventures Fund II, RA Capital Management are named among the investors backing Apogee Therapeutics.
What was the latest Apogee Therapeutics funding round?
The most recent disclosed round is a Series B, announced in December 2022.
Where is Apogee Therapeutics based?
Apogee Therapeutics is based in Waltham, MA.
When did Apogee Therapeutics last raise?
The last disclosed Apogee Therapeutics round closed in December 2022 at Series B.
Apogee Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Waltham below to benchmark round size and investor mix.
